Allergy treatment never ends.
We’re working on something that does.
AbstimX™: A patented two-antibody approach designed to restore immune regulation.
Nixxie, age 6
Treatment. Repeat.
Daily pills. Monthly injections. Years of therapy.
Modern treatments can work extremely well. But much of allergy care is built around ongoing control.
What if treatment could be finite?
Two antibodies.
One different idea.
Combining two established human immunoglobulin components in a patented investigational regimen.
Rather than continuously blocking one part of the allergic response, it is designed to work with the immune system’s own regulatory biology.
Finite course. Upstream approach. Still being proven.
Manage the response vs Restore regulation
Current therapy is largely built around controlling the allergic response.
AbstimX™ is designed to influence the regulation upstream.
The components aren’t new.
The combination is.
Human immunoglobulin products have decades of clinical use. NI’s patented combination and therapeutic approach are new.
AbstimX™ is protected in the US, China and Japan
Where we are
Patent estate
Granted in the US, China and Japan
Achieved
Published preclinical evidence
Six peer-reviewed publications across two species
Established
Canine clinical pilot study
Underway at an independent academic centre
In progress
Product definition
Specification, manufacturing and cost
In progress
Human studies
Not yet started
Not started
AbstimX™ is investigational. Efficacy in humans has not been established.
